Cargando…

Functional Variant rs4442975 Modulating FOXA1 Binding Affinity Can Influence Bone Marrow Suppression during Neoadjuvant Chemotherapy for Luminal A Type Breast Cancer

The expression of the transcription factor FOXA1 is associated with the prognosis of estrogen receptor (ER)-positive breast cancer, and the genetic variant rs4442975 can affect FOXA1 function. Therefore, we investigated the association between rs4442975 and the efficacy of neoadjuvant chemotherapy f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xin, Feng, Zhongxin, Li, Juan, Han, Yanyan, Su, Liyu, Wang, Feng, Yang, Yan, Zhang, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381587/ https://www.ncbi.nlm.nih.gov/pubmed/30881995 http://dx.doi.org/10.1155/2019/7073498

Ejemplares similares

A functional variant rs4442975 modulating FOXA1-binding affinity does not influence the risk or progression of breast cancer in Chinese Han population
por: Zhang, Yi, et al.
Publicado: (2016)

Lysosome‐dependent FOXA1 ubiquitination contributes to luminal lineage of advanced prostate cancer
por: Celada, Sherly I., et al.
Publicado: (2023)

DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer
por: Sigin, Vladimir O., et al.
Publicado: (2020)

FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact
por: Metovic, Jasna, et al.
Publicado: (2022)

FOXA1 expression affects the proliferation activity of luminal breast cancer stem cell populations
por: Tachi, Kana, et al.
Publicado: (2016)

Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
por: Thompson, Kevin J, et al.
Publicado: (2022)

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2019)

The Neutrophil to Lymphocyte Ratio Predicts the Response to Neoadjuvant Chemotherapy in Luminal B Breast Cancer
por: Rivas, Mauricio, et al.
Publicado: (2019)

Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression
por: Chen, F, et al.
Publicado: (2014)

Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases
por: Horimoto, Y, et al.
Publicado: (2015)

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer
por: Zhang, Zhuo, et al.
Publicado: (2021)

ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer
por: Gong, Yajie, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines
por: Warrick, Joshua I., et al.
Publicado: (2016)

Foxa1 and Foxa2 Are Required for Formation of the Intervertebral Discs
por: Maier, Jennifer A., et al.
Publicado: (2013)

Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression
por: Cowper-Sal·lari, Richard, et al.
Publicado: (2012)

Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy
por: Pfefferle, Adam D., et al.
Publicado: (2015)

Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy
por: Garufi, Giovanna, et al.
Publicado: (2023)

DNA Methylation and Prospects for Predicting the Therapeutic Effect of Neoadjuvant Chemotherapy for Triple-Negative and Luminal B Breast Cancer
por: Sigin, Vladimir O., et al.
Publicado: (2023)

FOXA1 can be modulated by HDAC3 in the progression of epithelial ovarian carcinoma
por: Lou, Tong, et al.
Publicado: (2022)

Androgen receptor and FOXA1 coexpression define a “luminal-AR” subtype of feline mammary carcinomas, spontaneous models of breast cancer
por: Dagher, Elie, et al.
Publicado: (2019)

FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer
por: Camolotto, Soledad A, et al.
Publicado: (2018)

Genetic polymorphisms of GGT1 gene (rs8135987, rs5751901 and rs2017869) are associated with neoadjuvant chemotherapy efficacy and toxicities in breast cancer patients
por: Sun, Lu, et al.
Publicado: (2023)

Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
por: Silva, Leonardo Roberto da, et al.
Publicado: (2019)

Integrative Genomic Analysis Identifies That SERPINA6-rs1998056 Regulated by FOXA/ERα Is Associated with Female Hepatocellular Carcinoma
por: Shen, Na, et al.
Publicado: (2014)

Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?
por: Kang, Wen-Zhe, et al.
Publicado: (2022)

The effect of FOXA2 rs1209523 on glucose-related phenotypes and risk of type 2 diabetes in Danish individuals
por: Banasik, Karina, et al.
Publicado: (2012)

Transcription factors Foxa1 and Foxa2 are required for adult dopamine neurons maintenance
por: Domanskyi, Andrii, et al.
Publicado: (2014)

Opposing Roles of FoxA1 and FoxA3 in Intrahepatic Cholangiocarcinoma Progression
por: Thanan, Raynoo, et al.
Publicado: (2020)

Pretreatment Diffusion-Weighted MRI Can Predict the Response to Neoadjuvant Chemotherapy in Patients with Nasopharyngeal Carcinoma
por: Zhang, Guo-Yi, et al.
Publicado: (2015)

FOXA1 in prostate cancer
por: Dong, Hui-Yu, et al.
Publicado: (2022)

MicroRNA-212 suppresses tumor growth of human hepatocellular carcinoma by targeting FOXA1
por: Dou, Changwei, et al.
Publicado: (2015)

FOXA1 Promotes Cell Proliferation and Suppresses Apoptosis in HCC by Directly Regulating miR-212-3p/FOXA1/AGR2 Signaling Pathway
por: Yuan, Zhen, et al.
Publicado: (2020)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Identification of Tumor Microenvironment-Related Prognostic Biomarkers in Luminal Breast Cancer
por: Wang, Yanyan, et al.
Publicado: (2020)

Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer
por: Carbonnier, Vincent, et al.
Publicado: (2023)

FOXA2 suppresses endometrial carcinogenesis and epithelial-mesenchymal transition by regulating enhancer activity
por: Sahoo, Subhransu S., et al.
Publicado: (2022)

Coordination of FOXA2 and SIRT6 suppresses the hepatocellular carcinoma progression through ZEB2 inhibition
por: Liu, Jinghua, et al.
Publicado: (2018)

FOXA1 defines cancer cell specificity
por: Zhang, Gaihua, et al.
Publicado: (2016)

Genetic Association Between CD143 rs4340 Polymorphism and Pneumonia risk: A Meta Analysis
por: Wang, Hong, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ado1ismso6ik9qb79j7pg7pq51